NPI registry status
Active
2026 NPPES data Research Study Specialist NPI 1831159649 MD
Verify on CMS → Anthony Szema, MD
Research Study Specialist in South Setauket, New York.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 485 in Research Study Specialist, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
492
Medicare Part D claims · 129 beneficiaries · Research Study Specialist avg: 601
Generic prescribing
0%
generic claims · 60% brand-name · higher generic rates reduce patient out-of-pocket costs
Industry payments
$39.86
1 payments · CMS Open Payments (Sunshine Act)
Source: CMS Medicare Part D Prescriber Public Use File, 2023
Compiled from official public sources by the PlainDoctor editorial team.
What the federal data shows
Anthony Szema, MD filed 492 Medicare Part D claims in 2023 as a Research Study Specialist in South Setauket, New York, prescribing 0% generic.
- 492
- Part D claims, 2023
- 0%
- generic prescribing
- $39.86
- industry payments (Sunshine Act)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Anthony Szema, MD's Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2023, across all CMS prescribers nationally
492 Top 38% higher than 62% of 1,370,886 prescribers
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Medicare Part D Prescriber Public Use File · 2023
What does the federal data show about Anthony Szema, MD?
Quality data not reportedPrimary specialty
Research Study Specialist
Medicare Part D claims
492 18% vs specialty avg
Specialty distribution in New York
How Research Study Specialist compares to other specialties among New York providers
Board certification
Not published by CMS
CMS does not publish a per-provider board-certification field in NPPES. PlainDoctor does not have a reliable per-specialty certification rate to show for Research Study Specialist. Verify directly:
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Anthony Szema, MD appears in the CMS NPPES registry as a Research Study Specialist provider holding MD credentials at 3771 NESCONSET HWY, South Setauket, NY, 11720, with a listed phone of (631) 675-6474. NPI 1831159649 was issued on 03/24/2006.
Medicare Part D records for calendar year 2023 show 492 prescription claims written by this provider, covering 129 Medicare beneficiaries and totaling roughly $1.6 million in drug spend, split 60% brand-name and 0% generic by claim count.
Research Study Specialist is a narrow specialty nationwide, with 485 enrolled providers across 42 states and an average of 601 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline.
Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1831159649 |
|---|---|
| Specialty | Research Study Specialist |
| Credentials | MD |
| Gender | Male |
| NPI Issued | 03/24/2006 |
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Anthony Szema, MD. Source: openpaymentsdata.cms.gov.
Total received
$40
Largest payer
GlaxoSmithKline, LLC.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context - New York NYSBPMC 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~100K New York medical licensees in 2023 - they are NOT specific to Anthony Szema, MD. To verify Anthony Szema, MD's current license status, search the NYSBPMC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
312
Total board actions, New York 2023
Across 302 cases
3.12
Actions per 1,000 licensees
New York statewide rate
probation
Most common action type
89 cases
NYSBPMC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the New York disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Brand-heavy
Anthony Szema, MD - brand share 60.0%
Research Study Specialist average
60% brand-name claims vs 0% generic, on 492 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
492
Total Claims
$1.6M
Total Drug Cost
129
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 901
- Total Day Supply
- 24,881
- Brand vs Generic
- 60% brand / 0% generic
- Brand Drug Cost
- $1.3M
Patient Demographics
- Average Patient Age
- 72.6 years
- Avg HCC Risk Score
- 1.06
- Gender Split
- 70% female / 30% male
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What Anthony Szema, MD prescribes most
Top Medicare Part D drugs by claim count, 2023
- Epinephrine
Epinephrine
81 claims
- Albuterol Sulfate …
Albuterol Sulfate Hfa
70 claims
- Trelegy Ellipta
Trelegy Ellipta
47 claims
- Symbicort
Symbicort
35 claims
- Ipratropium Bromide 25
Ipratropium Bromide
25 claims
- Montelukast Sodium 25
Montelukast Sodium
25 claims
- Prednisone 23
Prednisone
23 claims
- Fasenra 19
Fasenra
19 claims
| Drug | Claims |
|---|---|
| Epinephrine | 81 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 70 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 47 |
| Symbicort Budesonide/Formoterol Fumarate | 35 |
| Ipratropium Bromide | 25 |
| Montelukast Sodium | 25 |
| Prednisone | 23 |
| Fasenra Benralizumab | 19 |
| Xolair Omalizumab | 16 |
| Advair Diskus Fluticasone Propion/Salmeterol | 15 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Research Study Specialist Overview
How Anthony Szema, MD fits within the Research Study Specialist landscape nationally.
485
Research Study Specialist Providers in US
42
States with Research Study Specialist
601
Avg Claims per Provider
Anthony Szema, MD's 492 claims are below the specialty average of 601.
Nearby Research Study Specialist Providers in New York
Other clinicians with the same primary specialty enrolled in New York, drawn from the same CMS NPPES roster as Szema.
Dr. Alen Agaronov
SCD, RDN
New York, NY
Dr. Aries Arditi
PHD
Chappaqua, NY
Stephanie Belizaire
Rosedale, NY
Collette Bent
Queens Village, NY
Dr. Kuldeep Bhargava
PHD
New Hyde Park, NY
Compare Research Study Specialist nationally: see state-by-state distribution →
Before you book an appointment
Use this federal record as your verification checklist, not as a recommendation.
- Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
- Check the active license and any disciplinary history with the New York medical board, federal registration is not a license check. Credential verification guide
- Weigh a second option: compare this provider with a nearby Research Study Specialist peer on Medicare volume and prescribing patterns. Compare providers
Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
How to Find a Doctor
Step-by-step guide to choosing a provider
Verify Credentials
Check NPI, board certification & license status
Medical Specialties Explained
Who treats what and how specialties differ
Understanding Medicare Claims Data
What prescribing data reveals about a provider
In-Network vs Out-of-Network
How insurance networks affect your costs
Telehealth Guide
Virtual care options and coverage in 2026
Explore New York
Frequently Asked Questions
What is Anthony Szema, MD's specialty? ▼
Anthony Szema, MD specializes in Research Study Specialist and practices in South Setauket, New York. Credentials: MD.
How much does Anthony Szema, MD prescribe under Medicare Part D? ▼
In 2023, Anthony Szema, MD wrote 492 Medicare Part D claims totaling $1.6M in drug costs for 129 beneficiaries.
Where is Anthony Szema, MD located? ▼
Anthony Szema, MD is located at 3771 NESCONSET HWY, South Setauket, NY, 11720. Phone: (631) 675-6474.
What is Anthony Szema, MD's NPI number? ▼
Anthony Szema, MD's National Provider Identifier (NPI) is 1831159649, issued on 03/24/2006.
Does Anthony Szema, MD prescribe more brand-name or generic drugs? ▼
Anthony Szema, MD's prescribing is 60% brand-name and 0% generic drugs by claim count, with $1.3M in brand drug costs.
How many Research Study Specialist providers are there in the US? ▼
There are 485 Research Study Specialist providers across 42 states in the US. The average Research Study Specialist provider writes 601 Medicare Part D claims per year.
What drugs does Anthony Szema, MD prescribe most often? ▼
Based on 2023 Medicare Part D data, Anthony Szema, MD's most frequently prescribed drugs include Epinephrine, Albuterol Sulfate Hfa, Trelegy Ellipta. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Anthony Szema, MD accept Medicare? ▼
Anthony Szema, MD appears in CMS Medicare data with 492 Part D claims and 129 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Anthony Szema, MD's credentials? ▼
Anthony Szema, MD's NPI is 1831159649 with credentials MD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Compiled from official public sources by the PlainDoctor editorial team.
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.